Comparative Risk of Arterial Thromboembolic Events Between Aflibercept and Ranibizumab in Patients with Maculopathy: A Population-Based Retrospective Cohort Study.
Wan-Ju Annabelle LeeShih-Chieh ShaoTzu-Chi LiaoSwu-Jane LinChi-Chun LaiEdward Chia-Cheng LaiPublished in: BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy (2021)
The use of aflibercept in patients with maculopathy was associated with a lower risk of ATE than was the use of ranibizumab. There was no difference in mortality risk between the two groups. Our study could provide strong grounds for future prospective studies to confirm the findings.